Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patie
4/9 21:00
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival ( OS) at prede termined , independent interim analysis T rial results to be submitted for presentation at a future medical meeting Genmab and Seagen to engage in discussions with...